The present invention relates to F3 -peptide targeted lipid-based nanoparticles, adequate to encapsulate and delivery- one or more nucleic acids, comprising; a) one or more nucleic acids; b) one or more cationic lipids; c) one or more non- cationic lipids; d) one or more poly (ethylene glycol) - derivatized lipids; and e) one or more coupled targeting ligands which bind to the nucleolin receptor. The nanoparticles according to the invention have a high loading capacity, ability to protect the encapsulated nucleic acid, a size below 250 ran and a charge close to neutrality, which are adequate features for intravenous administration. The nanoparticles of the present inventon have the ability to selectively delivery a siRNA to cancer cells and/or endothelial cells from angiogenic blood vessels leading to an effective silencing of a target gene. These nanoparticles are used for the treatment of angiogenesis- dependent diseases, namely cancer, inflammation, an auto-immune disease or an ocular disorder.
|Publication status||Published - 29 Sep 2011|
- F3-peptide nanoparticles
- lipid based nanoparticles
- gene silencing
Nuno Moreira, J., Gomes-da-Silva, L. C., Bimbo, L., Oliveira Santos, A., Pedroso de Lima, M. C., & Simões, S. (2011). IPC No. A61K9/127. F3-Peptide targeted lipid-based nanoparticles useful for the treatment of angiogenesis-dependent diseases. (Patent No. WO2011119058).